Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Breast Cancer

  Free Subscription


1 Am J Clin Oncol
1 Am J Epidemiol
2 Ann Oncol
3 Ann Surg Oncol
4 Anticancer Res
2 BMC Cancer
3 Br J Cancer
3 Breast Cancer
2 Breast Cancer Res
14 Breast Cancer Res Treat
1 Cancer
1 Cancer Cell
1 Cancer Chemother Pharmacol
1 Cancer Res
6 Clin Breast Cancer
1 Clin Cancer Res
1 Clin Exp Metastasis
7 Eur Radiol
2 Int J Radiat Oncol Biol Phys
3 J Clin Oncol
1 J Natl Cancer Inst
3 J Surg Oncol
1 Lancet
3 Lancet Oncol
1 NPJ Breast Cancer
1 Oncol Rep
1 PLoS Biol
2 PLoS Comput Biol
3 PLoS One
2 Radiol Imaging Cancer
1 Radiologia (Engl Ed)

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Clin Oncol

  1. QURESHI Z, Jamil A, Fatima E, Altaf F, et al
    Efficacy of Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Comprehensive Systematic Review and Meta-analysis.
    Am J Clin Oncol. 2024 Jun 21. doi: 10.1097/COC.0000000000001121.
    PubMed         Abstract available

    Am J Epidemiol

  2. MALDONADO-CANON K, Mohl A, Obi N, Behrens S, et al
    The Healthy Participant Effect: insights and results from a population-based case-control study on breast cancer.
    Am J Epidemiol. 2024 Jun 24:kwae155. doi: 10.1093.
    PubMed         Abstract available

    Ann Oncol

  3. TARANTINO P, Tolaney SM
    Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes.
    Ann Oncol. 2024;35:579-581.

  4. ARECCO L, Bruzzone M, Bas R, Kim HJ, et al
    Impact of Hormone Receptor Status and Tumor Subtypes of Breast Cancer in Young BRCA Carriers.
    Ann Oncol. 2024 Jun 20:S0923-7534(24)00740-3. doi: 10.1016/j.annonc.2024.
    PubMed         Abstract available

    Ann Surg Oncol

  5. STRIJBOS BTM, Janssen L, Voogd AC, Zwaans WAR, et al
    Persistent Pain After Breast Cancer Treatment, an Underreported Burden for Breast Cancer Survivors.
    Ann Surg Oncol. 2024 Jun 28. doi: 10.1245/s10434-024-15682.
    PubMed         Abstract available

  6. CORTINA CS, Purdy A, Brazauskas R, Stachowiak SM, et al
    The Impact of a Breast Cancer Risk Assessment on the Decision for Gender-Affirming Chest Masculinization Surgery in Transgender and Gender-Diverse Individuals: A Pilot Single-Arm Educational Intervention Trial.
    Ann Surg Oncol. 2024 Jun 28. doi: 10.1245/s10434-024-15701.
    PubMed         Abstract available

  7. LEE EG, Lee DE, Jung SY, Han JH, et al
    ASO Author Reflections: Assessing the Efficacy of Multimodal Sentinel Lymph Node Mapping in Breast Cancer Patients After Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2024 Jun 24. doi: 10.1245/s10434-024-15580.

    Anticancer Res

  8. NIEDER C, Haukland EC, Mannsaker B
    Return to Work After Breast Cancer Treatment: An Electronic Health Record-based Study in North Norway.
    Anticancer Res. 2024;44:3193-3198.
    PubMed         Abstract available

  9. HEIDINGER M, Egle D, Piscuoglio S, Navarro-Aguadero MA, et al
    Extracellular Vesicle DNA Extraction and Sequencing in Ancient Serum Samples From Patients With Breast Cancer.
    Anticancer Res. 2024;44:2981-2988.
    PubMed         Abstract available

  10. TAO X, Na LI, Hu EX, Wang J, et al
    Clinical Diagnostic Value of circ-ARHGER28 for Breast Cancer and its Effect on MCF 7 Cell Proliferation and Apoptosis.
    Anticancer Res. 2024;44:2877-2886.
    PubMed         Abstract available

  11. WOO SH, Jung BC, Kim JY, Lee YH, et al
    PEMF Potentiates Doxorubicin-induced Late G(2) Arrest in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2024;44:2837-2846.
    PubMed         Abstract available

    BMC Cancer

  12. BOHANSKE MS, Momenzadeh K, van der Zwaal P, Hoogwater FJH, et al
    Computed tomography-based structural rigidity analysis can assess tumor- and treatment-induced changes in rat bones with metastatic lesions.
    BMC Cancer. 2024;24:767.
    PubMed         Abstract available

  13. OZORIO DUTRA SV, Schwab L, Coury J, Ji M, et al
    Process evaluation protocol plan for a home-based physical activity intervention versus educational intervention for persistent taxane-induced peripheral neuropathy (B-HAPI study): a randomized controlled trial.
    BMC Cancer. 2024;24:777.
    PubMed         Abstract available


  14. BELL KJ, Nickel B, Pathirana T, Blennerhassett M, et al
    Breast cancer screening from age 40 in the US.
    BMJ. 2024;385:q1353.

    Br J Cancer

  15. ZHU T, Huang YH, Li W, Wu CG, et al
    A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial.
    Br J Cancer. 2024 Jun 25. doi: 10.1038/s41416-024-02726.
    PubMed         Abstract available

  16. POUMEAUD F, Morisseau M, Cabel L, Goncalves A, et al
    Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.
    Br J Cancer. 2024 Jun 25. doi: 10.1038/s41416-024-02766.
    PubMed         Abstract available

  17. ZUO W, Wang Z, Qian J, Ma X, et al
    QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controll
    Br J Cancer. 2024 Jun 21. doi: 10.1038/s41416-024-02751.
    PubMed         Abstract available

    Breast Cancer

  18. KOYAMA Y, Nakashima K, Orihara S, Tsunoda H, et al
    Inter- and intra-observer variability of qualitative visual breast-composition assessment in mammography among Japanese physicians: a first multi-institutional observer performance study in Japan.
    Breast Cancer. 2024;31:671-683.
    PubMed         Abstract available

  19. MAITA KC, Avila FR, Torres-Guzman RA, Garcia JP, et al
    The usefulness of artificial intelligence in breast reconstruction: a systematic review.
    Breast Cancer. 2024;31:562-571.
    PubMed         Abstract available

  20. KATO S, Mori H, Saiga M, Watanabe S, et al
    Nipple-areolar complex malposition in breast reconstruction after nipple-sparing mastectomy: a multi-institutional retrospective observational study in Japan.
    Breast Cancer. 2024;31:649-658.
    PubMed         Abstract available

    Breast Cancer Res

  21. LU Y, Houson HA, Gallegos CA, Mascioni A, et al
    Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models.
    Breast Cancer Res. 2024;26:104.
    PubMed         Abstract available

  22. WANG D, Yang S, Lyu M, Xu L, et al
    Circular RNA HSDL2 promotes breast cancer progression via miR-7978 ZNF704 axis and regulating hippo signaling pathway.
    Breast Cancer Res. 2024;26:105.
    PubMed         Abstract available

    Breast Cancer Res Treat

  23. STEAD TS, Lu CY, Geletzke A, Butler E, et al
    Indocyanine green angiography guidance for vascular preservation in skin and nipple sparing mastectomy.
    Breast Cancer Res Treat. 2024;206:575-583.
    PubMed         Abstract available

  24. ROCA NAVARRO MJ, Oliver Goldaracena JM, Garrido Alonso D, Navarro Monforte Y, et al
    Pre-surgical cryoablation in
    Breast Cancer Res Treat. 2024;206:561-573.
    PubMed         Abstract available

    Letter to the editor: "Body composition measures as a determinant of alpelisib-related toxicity".
    Breast Cancer Res Treat. 2024;206:677.

  26. ROCQUE GB, Eltoum N, Caston NE, Williams CP, et al
    A randomized controlled trial of shared decision-making treatment planning process to enhance shared decision-making in patients with MBC.
    Breast Cancer Res Treat. 2024;206:483-493.
    PubMed         Abstract available

  27. JOHNSTON E, Cowan K, MacKenzie M, Patton S, et al
    Identifying research priorities for improving information and support for patients undergoing breast cancer surgery: a UK patient-centred priority setting project.
    Breast Cancer Res Treat. 2024 Jun 24. doi: 10.1007/s10549-024-07413.
    PubMed         Abstract available

  28. ZHANG D, Fang J, Shan J, Xu L, et al
    SCARB2 associates with tumor-infiltrating neutrophils and predicts poor prognosis in breast cancer.
    Breast Cancer Res Treat. 2024 Jun 24. doi: 10.1007/s10549-024-07401.
    PubMed         Abstract available

  29. SELIEM MA, Mohamadin AM, El-Sayed MIK, Ismail Y, et al
    The clinical signature of genetic variants and serum levels of macrophage migration inhibitory factor in Egyptian breast cancer patients.
    Breast Cancer Res Treat. 2024 Jun 25. doi: 10.1007/s10549-024-07393.
    PubMed         Abstract available

  30. MCCARTHY AM, Ehsan S, Hughes KS, Lehman CD, et al
    Feasibility of risk assessment for breast cancer molecular subtypes.
    Breast Cancer Res Treat. 2024 Jun 25. doi: 10.1007/s10549-024-07404.
    PubMed         Abstract available

  31. SINGAREEKA RAGHAVENDRA A, Liu D, Shen Y, Barcenas CH, et al
    Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience.
    Breast Cancer Res Treat. 2024 Jun 25. doi: 10.1007/s10549-024-07309.
    PubMed         Abstract available

  32. LAMMERS SWM, Geurts SME, Hermans KEPE, van Hellemond IEG, et al
    Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial.
    Breast Cancer Res Treat. 2024 Jun 28. doi: 10.1007/s10549-024-07411.
    PubMed         Abstract available

  33. SHIEN T, Tsuda H, Sasaki K, Mizusawa J, et al
    Comparison of proportions and prognostic impact of pathological complete response between evaluations of representative specimen and total specimen in primary breast cancer after neoadjuvant chemoradiotherapy: an ancillary study of JCOG0306.
    Breast Cancer Res Treat. 2024 Jun 27. doi: 10.1007/s10549-024-07408.
    PubMed         Abstract available

  34. IWAMOTO T, Niikura N, Watanabe K, Takeshita T, et al
    Prognostic value of the 21-Gene Breast Recurrence Score(R) assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).
    Breast Cancer Res Treat. 2024 Jun 26. doi: 10.1007/s10549-024-07414.
    PubMed         Abstract available

  35. CRONIN M, Lowery A, McInerney V, Wijns W, et al
    Understanding cardiac events in breast cancer (UCARE): pilot cardio-oncology assessment and surveillance pathway for breast cancer patients.
    Breast Cancer Res Treat. 2024 Jun 26. doi: 10.1007/s10549-024-07322.
    PubMed         Abstract available

  36. KIMMICK G, Pilehvari A, You W, Bonilla G, et al
    First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.
    Breast Cancer Res Treat. 2024 Jun 26. doi: 10.1007/s10549-024-07415.
    PubMed         Abstract available


  37. LU W, Giobbie-Hurder A, Tanasijevic A, Kassis SB, et al
    Acupuncture for hot flashes in hormone receptor-positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials.
    Cancer. 2024 Jun 24. doi: 10.1002/cncr.35374.
    PubMed         Abstract available

    Cancer Cell

  38. ELKHOLI IE, Rose AAN, Aguirre-Ghiso JA, Cote JF, et al
    How can we integrate the biology of breast cancer cell dormancy into clinical practice?
    Cancer Cell. 2024 Jun 12:S1535-6108(24)00191-0. doi: 10.1016/j.ccell.2024.
    PubMed         Abstract available

    Cancer Chemother Pharmacol

  39. MOEIN A, Jin JY, Wright MR, Wong H, et al
    Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic bre
    Cancer Chemother Pharmacol. 2024 Jun 27. doi: 10.1007/s00280-024-04690.
    PubMed         Abstract available

    Cancer Res

  40. MENEGOLLO M, Bentham RB, Henriques T, Ng SQ, et al
    Multi-State Gene Cluster Switches Determine the Adaptive Mitochondrial And Metabolic Landscape of Breast Cancer.
    Cancer Res. 2024 Jun 26. doi: 10.1158/0008-5472.CAN-23-3172.
    PubMed         Abstract available

    Clin Breast Cancer

  41. QADIR A, Singh N, Moe AAK, Cahoon G, et al
    Potential of MRI in Assessing Treatment Response After Neoadjuvant Radiation Therapy Treatment in Breast Cancer Patients: A Scoping Review.
    Clin Breast Cancer. 2024 May 31:S1526-8209(24)00136.
    PubMed         Abstract available

  42. CONNORS C, Al-Hilli Z
    De-escalation of Axillary Surgery After Neoadjuvant Therapy.
    Clin Breast Cancer. 2024;24:385-391.
    PubMed         Abstract available

  43. WEED C, Wang T, Mohan SC, Wang X, et al
    Comparison of Clinical Breast Exam to Breast MRI Surveillance in Patients Following Nipple-Sparing Mastectomy.
    Clin Breast Cancer. 2024;24:457-462.
    PubMed         Abstract available

  44. YI M, Lin Y, Lin Z, Xu Z, et al
    Biopsy or Follow-up: AI Improves the Clinical Strategy of US BI-RADS 4A Breast Nodules Using a Convolutional Neural Network.
    Clin Breast Cancer. 2024;24:e319-e332.
    PubMed         Abstract available

  45. GUO H, Zhang X, Wang JG, Kalika P, et al
    S-ketamine Infusion on Chronic Postoperative Pain Following Breast Cancer Surgery: A Randomized Double-Blind Placebo-Controlled Trial.
    Clin Breast Cancer. 2024 Jun 7:S1526-8209(24)00149.
    PubMed         Abstract available

  46. MITRI S, Roldan-Vasquez E, Flores R, Pardo J, et al
    Axillary Management Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer.
    Clin Breast Cancer. 2024 May 21:S1526-8209(24)00121.
    PubMed         Abstract available

    Clin Cancer Res

  47. SCHMIESTER L, Braso-Maristany F, Gonzalez-Farre B, Pascual T, et al
    Computational model predicts patient outcomes in Luminal B breast cancer treated with endocrine therapy and CDK4/6 inhibition.
    Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-24-0244.
    PubMed         Abstract available

    Clin Exp Metastasis

  48. CHEN K, Dong Y, He G, He X, et al
    UBTF mediates activation of L3MBTL2 to suppress NISCH expression through histone H2AK119 monoubiquitination modification in breast cancer.
    Clin Exp Metastasis. 2024 Jun 27. doi: 10.1007/s10585-024-10299.
    PubMed         Abstract available

    Eur Radiol

  49. LIEBERT A, Das BK, Kapsner LA, Eberle J, et al
    Smart forecasting of artifacts in contrast-enhanced breast MRI before contrast agent administration.
    Eur Radiol. 2024;34:4752-4763.
    PubMed         Abstract available

  50. GENNARO G, Povolo L, Del Genio S, Ciampani L, et al
    Using automated software evaluation to improve the performance of breast radiographers in tomosynthesis screening.
    Eur Radiol. 2024;34:4738-4749.
    PubMed         Abstract available

  51. WIELEMA M, Sijens PE, Pijnappel RM, De Bock GH, et al
    Image quality of DWI at breast MRI depends on the amount of fibroglandular tissue: implications for unenhanced screening.
    Eur Radiol. 2024;34:4730-4737.
    PubMed         Abstract available

  52. CHEN C, Turco S, Kapetas P, Mann R, et al
    Spatiotemporal analysis of contrast-enhanced ultrasound for differentiating between malignant and benign breast lesions.
    Eur Radiol. 2024;34:4764-4773.
    PubMed         Abstract available

  53. NISSAN N
    Pre-injection anticipation of artifacts in contrast-enhanced breast MRI: artificial intelligence harnessed for the aid once again.
    Eur Radiol. 2024;34:4750-4751.

    Dense breasts at breast cancer screening: can DWI-based breast MRI without contrast help us in the pursuit of personalized screening?
    Eur Radiol. 2024;34:4727-4729.

  55. WANG X, Jing L, Yan L, Wang P, et al
    A conditional inference tree model for predicting cancer risk of non-mass lesions detected on breast ultrasound.
    Eur Radiol. 2024;34:4776-4788.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  56. BEYDOUN H, Griffith KA, Jagsi R, Burmeister JW, et al
    Are We Missing Acute Toxicities Associated With Hypofractionated Breast Irradiation? A Report From a Large Multicenter Cohort Study.
    Int J Radiat Oncol Biol Phys. 2024;119:1092-1098.
    PubMed         Abstract available

  57. ASHA W, Al-Hilli Z, Djohan R, Budd GT, et al
    Neoadjuvant Reirradiation for Radiation Therapy-Associated Angiosarcoma of the Breast.
    Int J Radiat Oncol Biol Phys. 2024;119:1082-1085.
    PubMed         Abstract available

    J Clin Oncol

  58. TARANTINO P, Tayob N, Villacampa G, Dang C, et al
    Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
    J Clin Oncol. 2024 Jun 27:JCO2302170. doi: 10.1200/JCO.23.02170.
    PubMed         Abstract available

  59. SCHMIDT JA, Woolpert KM, Hjorth CF, Farkas DK, et al
    Social Characteristics and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer.
    J Clin Oncol. 2024 Jun 25:JCO2302643. doi: 10.1200/JCO.23.02643.
    PubMed         Abstract available

  60. KUSUMOTO M, Shimomura A, Shimizu C
    Shorter Duration of Trastuzumab Combined With Chemotherapy for Early Breast Cancer.
    J Clin Oncol. 2024 Jun 24:JCO2302407. doi: 10.1200/JCO.23.02407.

    J Natl Cancer Inst

  61. DENT R, Cortes J, Pusztai L, McArthur H, et al
    Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study.
    J Natl Cancer Inst. 2024 Jun 24:djae129. doi: 10.1093.
    PubMed         Abstract available

    J Surg Oncol

  62. KIM M, Ali B, Graziano FD, Colvin K, et al
    Analyzing mastectomy and reconstruction weight in immediate autologous breast reconstruction: A preliminary study.
    J Surg Oncol. 2024;129:1466-1474.
    PubMed         Abstract available

  63. REYES-MONASTERIO A, Moller MG, Lozada-Martinez ID, Narvaez-Rojas AR, et al
    Bridging frontiers: The role of a Global Breast Research Working Group.
    J Surg Oncol. 2024;129:1507-1514.
    PubMed         Abstract available

  64. HYAMS DM, Bareket-Samish A, Rocha JEB, Diaz-Botero S, et al
    Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays.
    J Surg Oncol. 2024 Jun 24. doi: 10.1002/jso.27692.
    PubMed         Abstract available


  65. DELALOGE S, Khan SA, Wesseling J, Whelan T, et al
    Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.
    Lancet. 2024;403:2734-2746.
    PubMed         Abstract available

    Lancet Oncol

    New Canadian draft breast screening guidelines issued.
    Lancet Oncol. 2024;25:836.

  67. GOURD E
    Olufunmilayo Olopade-preventive oncologist using genetics to fight breast cancer in high-risk populations.
    Lancet Oncol. 2024;25:839.

  68. OFUYA M
    Overcoming barriers to early breast cancer presentation in Nigeria.
    Lancet Oncol. 2024;25:840.

    NPJ Breast Cancer

  69. DI GIROLAMO C, Cammarata G, Giordano L, Zengarini N, et al
    Contextual and individual inequalities in breast cancer screening participation and outcomes in Turin (North-West Italy).
    NPJ Breast Cancer. 2024;10:51.
    PubMed         Abstract available

    Oncol Rep

  70. LI H, Li X, Du W
    Interplay between Wnt signaling molecules and exosomal miRNAs in breast cancer (Review).
    Oncol Rep. 2024;52:107.
    PubMed         Abstract available

    PLoS Biol

  71. NIU M, He Y, Xu J, Ding L, et al
    Retraction: Noncanonical TGF-beta signaling leads to FBXO3-mediated degradation of DeltaNp63alpha promoting breast cancer metastasis and poor clinical prognosis.
    PLoS Biol. 2024;22:e3002708.

    PLoS Comput Biol

  72. VANDERDOES J, Marceaux C, Yokote K, Asselin-Labat ML, et al
    Using random forests to uncover the predictive power of distance-varying cell interactions in tumor microenvironments.
    PLoS Comput Biol. 2024;20:e1011361.
    PubMed         Abstract available

  73. DIMITRIOU NM, Flores-Torres S, Kyriakidou M, Kinsella JM, et al
    Cancer cell sedimentation in 3D cultures reveals active migration regulated by self-generated gradients and adhesion sites.
    PLoS Comput Biol. 2024;20:e1012112.
    PubMed         Abstract available

    PLoS One

  74. ALEM T, Nigatu D, Birara A, Fetene T, et al
    Quality of life of breast cancer patients in Amhara region, Ethiopia: A cross-sectional study.
    PLoS One. 2024;19:e0305263.
    PubMed         Abstract available

  75. REY-VARGAS L, Bejarano-Rivera LM, Serrano-Gomez SJ
    Genetic ancestry is related to potential sources of breast cancer health disparities among Colombian women.
    PLoS One. 2024;19:e0306037.
    PubMed         Abstract available

  76. SAMMAN N, Mohabatkar H, Behbahani M, Ganjlikhani Hakemi M, et al
    Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model.
    PLoS One. 2024;19:e0306117.
    PubMed         Abstract available

    Radiol Imaging Cancer

  77. FIELDS BKK, Joe BN
    Digital Breast Tomosynthesis for Nonimplant-displaced Views May Be Safely Omitted at Screening Mammography.
    Radiol Imaging Cancer. 2024;6:e249014.

    Innovative Advances in Molecular Breast Imaging Biopsy.
    Radiol Imaging Cancer. 2024;6:e240135.

    Radiologia (Engl Ed)

  79. DIAZ DE BUSTAMANTE DURBAN T, Roca Navarro MJ, Navarro Monforte Y, Garrido Alonso D, et al
    Ultrasound-guided cryoablation: Our experience in percutaneous treatment as an alternative to surgery for fibroadenomas of the breast lesions.
    Radiologia (Engl Ed). 2024;66:228-235.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.